Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 10/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3774708 | 0.85 | JAK3 (0.41) | TGFBR1DYRK1A | |
| SCHEMBL2522143 | 0.74 | ADORA2B (0.36) | TGFBR1PDPK1SYK | |
| SCHEMBL5474088 | 0.72 | CLK4 (0.44) | TGFBR1EGFR | |
| SCHEMBL3639337 | 0.68 | DYRK1A (0.44) | TGFBR1EGFRPIK3CADYRK1A | |
| Hydrazine SCHEMBL15398735 | 0.61 | BRAF (0.41) | TGFBR1DYRK1A | |
| Ammonia Solution, Strong SCHEMBL3777371 | 0.60 | TGFBR1 (0.35) | TGFBR1PIK3CA | |
| SCHEMBL29702869 | 0.60 | DYRK1A (0.59) | EGFRDYRK1A | |
| SCHEMBL397656 | 0.60 | DYRK1A (0.59) | EGFRDYRK1A | |
| SCHEMBL28048489 | 0.59 | DYRK1A (0.57) | EGFRDYRK1A | |
| Hydrochloric Acid SCHEMBL3353317 | 0.59 | DYRK1A (0.57) | EGFRDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140005198-A1 | RAF KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2014-01-02 | — | — | US | disclosed |
| US-8557830-B2 | RAF kinase modulators and methods of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20100324047-A1 | RAF KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324047-A1 | RAF KINASE MODULATORS AND METHODS OF USE | BRAF, RAF1, ARAF | TGFBR1 2587/4885EGFR 344/4885PIK3CA 59/4885 |
| US-20140005198-A1 | RAF KINASE MODULATORS AND METHODS OF USE | BRAF, RAF1, ARAF | TGFBR1 2640/4885EGFR 388/4885PIK3CA 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.